Estos son una serie de resúmenes de publicaciones sobre evidencia científica de la Acupuntura en Pubmed.com.
These are abstracts from Pubmed.com on the cientific basis of Acupuncture
PET imaging of brain function while puncturing the acupoint ST36.
· Yin L,
· Jin X,
· Qiao W,
· Sun J,
· Shi X,
· Tian J,
· Yin D,
· Yao S,
· Shao M,
· Zeng H,
· Shan B,
· Tang Y,
· Zhu K.
Neuroinformatics Center, PLA General Hospital, Beijing 100853, China. firstname.lastname@example.org
OBJECTIVE: To explore the experimental method of obtaining Positron Emission Tomography (PET) imaging evidence of changes in cerebral function by puncturing the Stomach 36 (ST36, Zusanli) acupoint. METHODS: Data on changes of cerebral glycometabolism were obtained from six healthy male volunteers with positron emission tomography. Visual experimental evidence, as well as statistical parametric mapping (SPM), was gathered while puncturing the ST36 (Zusanli, right leg) acupoint. RESULTS: There was increased glycometabolism in the hypothalamus, head of the caudate nucleus, temporal lobe, the sinistral cerebellum, postcentral gyrus, and brain stem while the acupoint ST36 was being punctured. CONCLUSIONS: Acupuncture on ST36 can lead to increase in glycometabolism in the vegetative nerve centers, which is correlated with gastric function. Visual experimental evidence of ST36 acupuncturing on functional gastrointestinal disorder was obtained in our study.
PMID: 14687469 [PubMed – indexed for MEDLINE]
[Article in Chinese]
· Shapo GR,
· Ma L,
· Liu C.
Department of Imaging, The Second Hospital of Shandong University, Jinan. email@example.com
OBJECTIVE: To observe the effect of needling at Weizhong (BL 40) acupoint in inducing metabolic changes in brain with positron emission tomography and dynamic contrast (PET/CT) imaging for exploring the mechanism of central regulation of acupuncture. METHODS: PET/CT was performed before and during needling Weizhong acupoint of right leg by electro-acupuncture in 8 healthy volunteers, and also in other 8 subjects without any acupoint stimulation for control. Difference of brain functional images between the two groups before and during needling was analyzed by pairing t-test with statistical parametric mapping. RESULTS: The needling evoked mean activated cerebral functional regions were: left Broadmann area (BA) 10, 11, 22, 38, 39, 40, 44-46, right BA10, bilateral BA18, 19, and left cerebellar cortex, claustrum and insula (t > 3.36, P < 0.01, k >30 voxels); its mean inhibited brain functional regions were: bilateral BA24, left BA7, 8, 19, 40, right BA 1, 3, 6, 20, 44, and left substantia nigra. CONCLUSION: There is a certain connection between Weizhong acupoint and the brain. Needling this acupoint could exert effects through activating or inhibiting brain function in specific regions and neurohumoral regulation. One of the central regulation mechanisms of acupuncture was functional activation in superior, middle, and inferior frontal gyrus, insula and cerebellum and functional inhibition in callosal gyrus, lobi parietalis and substantia nigra. This study further demonstrated PET/CT is useful in revealing TCM meridian theory and could provide objective proof of central regulation for acupuncture treatment.
PMID: 17186722 [PubMed – in process]
[Article in Chinese]
· Dong JC,
· Li J,
· Zuo CT.
Affiliated Huashan Hospital to Fudan University, Shanghai 200040.
OBJECTIVE: To study the different effect of needling at different meridian points (MP) on different cerebral functional regions by using positron emission tomography and cerebral function tracer 18F-fluorodeoxy glucose to observe the effect of electro-acupuncture (EA) stimulation at Yin MP or Yang MP on local cerebral glucose metabolism in 30 healthy volunteers. METHODS: The thirty subjects were randomly divided into 2 groups, the 12 subjects in the Yang MP group treated by needling at Hegu (LI4), Quchi (LI11), Zusanli (St36) and Shangjuxu (St37), the 18 subjects in the Yin MP group treated by needling at Neiguan (Pc6), Chize (Lu5), Sanyinjiao (Sp6) and Yinlingquan (Sp9). All the needling was conducted at one side of body. RESULTS: After needling at Yang MP, the cerebral glucose metabolism was elevated in bilateral cross region of frontal lobe and temporal lobe, parietal lobe, thalamus and basal ganglia, and in contralateral cerebellum and hippocampus. After needling at Yin MP, the cerebral glucose metabolism was lowered in bilateral cross region of frontal and temporal lobe, contralateral temporal lobe, cerebellum and thalamus, and was elevated in homolateral hippocampus and caudate nucleus. CONCLUSION: Under physiological condition, the regulatory effects of acupuncture on central nervous system would be different when needling at different MP.
PMID: 12585145 [PubMed – indexed for MEDLINE]
As you remember we have isolated 12 peptides produced by the body after AP
against breast cancer, as described at <http://www.sanare.no/>
Now we have got the results from Nottingham, and the results are as
We have now completed the first in vitro study at the University of
Nottingham, which showed very promising results. As in Massachussetts, the
peptide mixture gave a 30% reduction of cell growth on the two cell lines
TMX228 and MCF7. The reduction was observed in Massachusetts after 24 hours,
and in this very study it was checked after 96 hours. This implies that the
peptides are most likely metabolized by the cells after 24-48 hrs, and their
effects therefore stop on their absence (naturally). This requires therefore
a new dose to be added or «protecting» the peptides from the cell machinery.
The positive controls, Tamoxifen and DXRB on the other hand are slower to
kill the cells, but after 96 hours reach to 80% . This is self-explanatory
because their synthetic structure is not recognized by the body and
therefore endures longer and gives therefore a slower but stronger effect.
In order to prolong the peptides effect to reach 80%-100% reduction, we are
now starting a series of experiments where we will identify when the
peptides are digested within the cells, and once knowing it, evaluate if
adding new doses or «protect» the peptides to last longer is the best
alternative. The modification of therapeutic peptides to increase their
lifetime is common and can prolong the cell-killing signal to match the
other medicines if not superceed them.
Results on this are awaited by mid April. Choosing to protect the peptides
will yield new costs which will be evaluated later against the costs of
increasing the frequency of the dose non-protected peptides.
The studies showed also that the peptides had an even stronger effect, to
our surpise, on cholon cancer cells. The effect reached a 45% reduction of
cells after 96 hours. This positive and unexpected finding leads us to
contemplate the inclusion of «colon cancer therpeutic peptides» in our
future planning, in addition to breast cancer therepeutic peptides.
Also very positively, our peptides were tested against the normal cell line,
also called fibroblast line (46BR1G1) and showed not to harm its growth.
This gives us reassuring knowledge on the present selective nature of the
peptides in avoiding healthy cells.
Three other new breast cancer cell lines were added in the experiment, and
the effect on these was on the other hand minimal. These three cell lines
are more aggressive than others, and the regular medicines have also a lower
effect on these, however more potent than our peptides. For this reason, we
initiate an additional investigation into a different compound-mixture for
these particularly harsh cell lines only. The compound mixture will be
composed of 5 selected peptides from the 12, which have shown from UMASS to
be only cellgrowth-reducing. This compound mixture will also be tested for
toxicology-aspects on the same fibroblast cell line, and the MCF7 line also,
so we can confirm its selective nature towards the healthy celles, and
observe if they act differently on the MCF7 (which is already killed by the
complete mixture). More results on this will also be awaited in April.
Additionally, a moderate reduction of 10% was observed on prostate cancer
cells, which we will consider in the future to investigate further.
We have therefore three tasks to explore in April and May:
1. Dose-dynamics of the 12-compound mixture on TMX228 and MCF7 cells, to
find when the effect ceases, so to explore whether to increase doses or make
2. Dose-response analysis on the new 5-compound mixture on the harsh
MDA-cell lines, and toxicology check on healthy cells.
3. Study alternative solvents to better solve the peptides for cell culture
For product-planning, we have now two gateways to explore in the future:
breast cancer therapeutic peptides and colon cancer therapeutic peptides.
The latter will be discussed when we reach the inititation of live-model
studies (mice) in June and we are open for opinions by our investors!
With all the best,
Sanare A.S. recently isolated from the blood of a female patient with breast cancer 12 bioactive peptides, after treatment with acupuncture. The bioactive peptides were tested at the University of Massachusetts, U.S.A., and showed to stop the growth of three breast cancer cell lines in only 24 hours, at six concentrations. The cell growth reduction reached up to 30%, while Tamoxifen, which is the regular therapeutic drug against breast cancer showed no effects at that time. The mixture showed strong inhibitory effects on the MCF7 cell line and the particularly aggressive and Tamoxifen-resistant TMX2-28 cell line. The third breast cancer cell line, T47D was also inhibited. The twelve oligopeptides showed also effective action against the breast cancer cell lines when applied individually
Identification of twelve non-toxic oligopeptides with cytostatic effects on three breast cancer cell lines.
We report a significant detection of bioactive content with anti-tumor effects in the blood of a patient needled with acupuncture. Protein concentration estimations indicated an increase of 0.48mg/mL after an acupuncture needle was inserted at a specific point in the breast cancer-affected patient. This increase was analyzed using 2D HPLC coupled with a MS/MS spectrometer. The analysis resolved twelve oligopeptides sequences that were synthesized and tested on three breast cancer cell lines in vitro. The tests showed that the peptides carried significant tumor-inhibiting properties and reduced cancer cell growth up to 30% after only 24 hours.
What is Sanare’s activity? Are you in a hurry or looking for a brief explanation of Sanare’s activity? Read more…
December 07: Sanare A.S. has signed the contract with Pre-clinical Oncology Services (PRECOS) at the University of Nottingham for pre-clinical testing. Read more...
July 07: Patent of the peptide mixture against breast cancer registered at the Norwegian Patent Office, reg. number 20073884. Read more...
Most interesting results.
What do you know of the peptide and the mechanism of it’s function? Is it a
receptor mediated action? If yes is it a competitive or a non competitive
action? If it is a competitive action it may not be that the peptide is
metabolised but ruled out by the number of new receptors produced by the
Is it a receptor on the cell surface triggering a change in the genetic
expression of the cancer cell? Is this receptor a specific cancer receptor?